US 12,275,770 B2
Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
Shannon Mullican, Spring House, PA (US); Matthew M. Rankin, Spring House, PA (US); Xiefan Lin-Schmidt, Spring House, PA (US); Chichi Huang, Spring House, PA (US); Jennifer Furman, San Diego, CA (US); Songmao Zheng, Spring House, PA (US); Shamina Rangwala, Spring House, PA (US); and Serena Nelson, San Diego, CA (US)
Assigned to Janssen Sciences Ireland Unlimited Company, Cork (IE)
Filed by Janssen Sciences Ireland Unlimited Company, Cork (IE)
Filed on Jun. 9, 2023, as Appl. No. 18/332,690.
Application 18/332,690 is a division of application No. 17/309,114, granted, now 11,713,345, previously published as PCT/IB2019/059029, filed on Oct. 22, 2019.
Claims priority of provisional application 62/748,603, filed on Oct. 22, 2018.
Prior Publication US 2023/0322888 A1, Oct. 12, 2023
Int. Cl. A61K 38/00 (2006.01); C07K 14/475 (2006.01); C07K 14/605 (2006.01); C12N 15/63 (2006.01)
CPC C07K 14/605 (2013.01) [C07K 14/475 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01)] 15 Claims
 
1. A method for treating obesity, the method comprising administering to the subject an effective amount of a glucagon-like peptide-1 (GLP-1)/growth differentiation factor 15 (GDF 15) fusion protein, wherein the GLP-1-GDF 15 fusion protein comprises a GLP-1 peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF 15 protein, wherein the GLP-1 peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4, and wherein the GDF15 protein comprises an amino acid sequence selected from SEQ ID NO: 31 or SEQ ID NO: 32.